Kyntra Bio Statistics
Total Valuation
Kyntra Bio has a market cap or net worth of $28.95 million. The enterprise value is -$62.37 million.
| Market Cap | 28.95M |
| Enterprise Value | -62.37M |
Important Dates
The last earnings date was Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kyntra Bio has 4.05 million shares outstanding. The number of shares has increased by 0.32% in one year.
| Current Share Class | 4.05M |
| Shares Outstanding | 4.05M |
| Shares Change (YoY) | +0.32% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 2.15% |
| Owned by Institutions (%) | 12.31% |
| Float | 3.56M |
Valuation Ratios
The trailing PE ratio is 0.16.
| PE Ratio | 0.16 |
| Forward PE | n/a |
| PS Ratio | 6.27 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.69
| Current Ratio | 2.69 |
| Quick Ratio | 2.54 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.41 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -22.50% |
| Return on Invested Capital (ROIC) | -68.57% |
| Return on Capital Employed (ROCE) | -77.26% |
| Weighted Average Cost of Capital (WACC) | 9.99% |
| Revenue Per Employee | $135,765 |
| Profits Per Employee | $5.39M |
| Employee Count | 34 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 7.50 |
Taxes
| Income Tax | -1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.73% in the last 52 weeks. The beta is 1.04, so Kyntra Bio's price volatility has been similar to the market average.
| Beta (5Y) | 1.04 |
| 52-Week Price Change | -36.73% |
| 50-Day Moving Average | 7.09 |
| 200-Day Moving Average | 7.72 |
| Relative Strength Index (RSI) | 53.18 |
| Average Volume (20 Days) | 8,304 |
Short Selling Information
The latest short interest is 97,565, so 2.41% of the outstanding shares have been sold short.
| Short Interest | 97,565 |
| Short Previous Month | 97,707 |
| Short % of Shares Out | 2.41% |
| Short % of Float | 2.74% |
| Short Ratio (days to cover) | 9.10 |
Income Statement
In the last 12 months, Kyntra Bio had revenue of $4.62 million and earned $183.19 million in profits. Earnings per share was $45.27.
| Revenue | 4.62M |
| Gross Profit | -22.58M |
| Operating Income | -50.25M |
| Pretax Income | -30.91M |
| Net Income | 183.19M |
| EBITDA | -50.04M |
| EBIT | -50.25M |
| Earnings Per Share (EPS) | $45.27 |
Balance Sheet
The company has $91.32 million in cash and no debt, with a net cash position of $91.32 million or $22.55 per share.
| Cash & Cash Equivalents | 91.32M |
| Total Debt | n/a |
| Net Cash | 91.32M |
| Net Cash Per Share | $22.55 |
| Equity (Book Value) | -8.14M |
| Book Value Per Share | -7.44 |
| Working Capital | 60.79M |
Cash Flow
In the last 12 months, operating cash flow was -$38.05 million and capital expenditures -$9,000, giving a free cash flow of -$38.06 million.
| Operating Cash Flow | -38.05M |
| Capital Expenditures | -9,000 |
| Depreciation & Amortization | 213,000 |
| Net Borrowing | -80.56M |
| Free Cash Flow | -38.06M |
| FCF Per Share | -$9.40 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,088.56% |
| Pretax Margin | -669.71% |
| Profit Margin | 3,968.63% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kyntra Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.32% |
| Shareholder Yield | -0.32% |
| Earnings Yield | 632.76% |
| FCF Yield | -131.47% |
Analyst Forecast
The average price target for Kyntra Bio is $39.00, which is 445.46% higher than the current price. The consensus rating is "Buy".
| Price Target | $39.00 |
| Price Target Difference | 445.46% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 7.15% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 17, 2025. It was a reverse split with a ratio of 1:25.
| Last Split Date | Jun 17, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
Kyntra Bio has an Altman Z-Score of -24.36 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -24.36 |
| Piotroski F-Score | 3 |